FRANKFURT, Feb 6 (Reuters) - German Merck KGaA said on Tuesday a U.S. regulator has asked for more data on a new formulation of its multiple sclerosis drug Rebif, a move that could delay approval for the drug to come to the market.
FRANKFURT, Feb 6 (Reuters) - German Merck KGaA said on Tuesday a U.S. regulator has asked for more data on a new formulation of its multiple sclerosis drug Rebif, a move that could delay approval for the drug to come to the market.
